LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Cytokinetics Inc

Fechado

SetorSaúde

32.28 0.69

Visão Geral

Variação de preço das ações

24h

Atual

Mín

32.06

Máximo

32.77

Indicadores-chave

By Trading Economics

Rendimento

-11M

-161M

Vendas

-15M

1.6M

EPS

-1.36

Margem de lucro

-10,220.139

Funcionários

498

EBITDA

-11M

-136M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+132.06% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-1.2B

3.7B

Abertura anterior

31.59

Fecho anterior

32.28

Sentimento de Notícias

By Acuity

50%

50%

167 / 380 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Cytokinetics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de abr. de 2025, 09:30 UTC

Principais Notícias

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

Comparação entre Pares

Variação de preço

Cytokinetics Inc Previsão

Preço-alvo

By TipRanks

132.06% parte superior

Previsão para 12 meses

Média 75.21 USD  132.06%

Máximo 120 USD

Mínimo 41 USD

Com base em 17 analistas de Wall Street que oferecem metas de preço de 12 meses para Cytokinetics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

17 ratings

15

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

32.3 / 40.43Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

167 / 380 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.